Eli Lilly and Co.

Lilly CEO says he's not interested in Pfizer animal unit

October 5, 2011
Bloomberg News
Drugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter said Wednesday.
More

Eli Lilly, Turkish firm in talks to sell drugs in 26 nations

October 3, 2011
Bloomberg News
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
More

Lilly's Alimta get favorable opinion for new use in Europe

September 26, 2011
J.K. Wall
If approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
More

Debate rages over whether Lilly's Byetta lifts cancer risk

September 16, 2011
Bloomberg News
A German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
More

FDA gets new report on Lilly diabetes drug

September 12, 2011
Associated Press
Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
More

FDA deal with drugmakers raises user fees 6 percent

September 1, 2011
Bloomberg News
Drugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.
More

Lilly spent $1.9M lobbying feds in first quarter

August 21, 2011
Associated Press
Eli Lilly and Co. spent $1.9 million lobbying the federal government in the first quarter, focusing on the health care overhaul and overseas pricing reform, among many other issues.
More

Eli Lilly's Elanco unit blossoming at just the right timeRestricted Content

July 30, 2011
Greg Andrews
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
More

Lilly wins appeals court ruling in Strattera patent case

July 29, 2011
Bloomberg News
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s patent on attention-deficit treatment Strattera was invalid.
More

Despite sales spike, Effient has middling prospects

July 25, 2011
J.K. Wall
Remember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
More

Lilly stock rises after drugmaker reports higher sales

July 21, 2011
Investors responded favorably Thursday to Eli Lilly and Co.’s surprisingly strong second-quarter revenue, even though its profit fell due to rapid spending on marketing and research.
More

Pfizer won’t break up animal unit for potential Lilly bid

July 21, 2011
Bloomberg News
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
More

Lilly profit falls, but forecast rises after second quarter

July 21, 2011
J.K. Wall
Second-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
More

Lilly: Alzheimer's patients on failed drug didn’t improve

July 19, 2011
Bloomberg News
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
More

FDA says potential diabetes drug may cause cancer

July 18, 2011
Bloomberg News
Dapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar drugs.
More

Lilly's Cialis finally overtakes Viagra

July 11, 2011
J.K. Wall
Why do drugmakers still pursue so many me-too drugs? Because, if marketed well, they can be extremely lucrative. Just ask Eli Lilly and Co. about its drug Cialis.
More

Lechleiter: German drug pricing creates 'uncertainty' for Lilly

July 11, 2011
Bloomberg News
Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy creates “uncertainty” for the company’s business planning.
More

Eli Lilly using big dividend to prevent investor exodusRestricted Content

July 9, 2011
Greg Andrews
Lilly executives are emphatic that they have no plans to reduce the company's 49-cents-a-share quarterly cash dividend, which gives the stock a rich annual yield of 5.2 percent.
More

J&J completes sale of animal-drug business to Lilly

July 7, 2011
Associated Press
Janssen Pharmaceutica said Thursday it has completed the sale of its animal health business to Eli Lilly and Co. Inc.
More

Lilly loses bid to end revived Zyprexa U.K. patent case

July 5, 2011
Bloomberg News
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
More

Timing good for 2-in-1 biotech drugs

July 5, 2011
J.K. Wall
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
More

R&D spending soars above value of new drugs

July 5, 2011
J.K. Wall
To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.
More

Lilly asks judge to reject U.K. Zyprexa case

July 5, 2011
Bloomberg News
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
More

Lilly plans 10 drugs in final-stage trials by year's end

June 30, 2011
Bloomberg News
Lilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s disease, up from seven in 2005, the Indianapolis-based company said Thursday.
More

Lilly plans more investment in two-in-one drugs

June 28, 2011
J.K. Wall
Indianapolis-based drugmaker Eli Lilly on Tuesday will announce a multimillion-dollar investment to develop drugs that act like two medicines in one. Lilly plans to add more scientists to back the effort.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Of what value is selling alcoholic beverages to State Fair patrons when there are many families with children attending. Is this the message we want to give children attending and participating in the Fair, another venue with alooholic consumption onsite. Is this to promote beer and wine production in the state which are great for the breweries and wineries, but where does this end up 10-15 years from now, lots more drinkers for the alcoholic contents. If these drinks are so important, why not remove the alcohol content and the flavor and drink itself similar to soft drinks would be the novelty, not the alcoholic content and its affects on the drinker. There is no social or material benefit from drinking alcoholic beverages, mostly people want to get slightly or highly drunk.

  2. I did;nt know anyone in Indiana could count- WHY did they NOT SAY just HOW this would be enforced? Because it WON;T! NOW- with that said- BIG BROTHER is ALIVE in this Article-why take any comment if it won't appease YOU PEOPLE- that's NOT American- with EVERYTHING you indicated is NOT said-I can see WHY it say's o Comments- YOU are COMMIES- BIG BROTHER and most likely- voted for Obama!

  3. In Europe there are schools for hairdressing but you don't get a license afterwards but you are required to assist in turkey and Italy its 7 years in japan it's 10 years England 2 so these people who assist know how to do hair their not just anybody and if your an owner and you hire someone with no experience then ur an idiot I've known stylist from different countries with no license but they are professional clean and safe they have no license but they have experience a license doesn't mean anything look at all the bad hairdressers in the world that have fried peoples hair okay but they have a license doesn't make them a professional at their job I think they should get rid of it because stateboard robs stylist and owners and they fine you for the dumbest f***ing things oh ur license isn't displayed 100$ oh ur wearing open toe shoes fine, oh there's ONE HAIR IN UR BRUSH that's a fine it's like really? So I think they need to go or ease up on their regulations because their too strict

  4. Exciting times in Carmel.

  5. Twenty years ago when we moved to Indy I was a stay at home mom and knew not very many people.WIBC was my family and friends for the most part. It was informative, civil, and humerous with Dave the KING. Terri, Jeff, Stever, Big Joe, Matt, Pat and Crumie. I loved them all, and they seemed to love each other. I didn't mind Greg Garrison, but I was not a Rush fan. NOW I can't stand Chicks and all their giggly opinions. Tony Katz is to abrasive that early in the morning(or really any time). I will tune in on Saturday morning for the usual fun and priceless information from Pat and Crumie, mornings it will be 90.1

ADVERTISEMENT